Aflibercept (VEGF Trap): One more double-edged sword of anti-VEGF therapy for cancer?

Clinical and Translational Oncology

Volumn 12, Issue 8, 2010, Pages 526-532

  Jin, Ketao ^a,b   Shen, Yanping ^a   He, Kuifeng ^a   Xu, Zhenzhen ^c   Li, Guangliang ^a   Teng, Lisong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Zhuji Hospital   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Adverse effect; Aflibercept; Antiangiogenesis; Vascular endothelial growth factor; VEGF Trap

Indexed keywords

AFLIBERCEPT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTHRALGIA; ASTHENIA; BACKACHE; BLEEDING; BLURRED VISION; BONE PAIN; BRAIN DISEASE; BRAIN ISCHEMIA; BREAST CANCER; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONFUSION; CONSTIPATION; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TARGETING; DRUG TOLERABILITY; DYSPHORIA; DYSPNEA; EPISTAXIS; EWING SARCOMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; GLIOMA; GYNECOLOGIC CANCER; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HEPATOBLASTOMA; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY PAIN; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MYALGIA; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; OPHTHALMOPLEGIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; RECURRENT CANCER; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; ULCER; UNSTABLE ANGINA PECTORIS; VOICE;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; HYPERTENSION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEINURIA; RECOMBINANT FUSION PROTEINS; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77958198446     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0550-4     Document Type: Review

References (56)

1. C. Wulff H. Wilson S.J. Wiegand, et al. 2002 Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2 Endocrinol 143 2797 2807 1:CAS:528:DC%2BD38XltVymtL8%3D 10.1210/en.143.7.2797 (Pubitemid 34701344)
2. E.S. Kim A. Serur J. Huang, et al. 2002 Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proc Natl Acad Sci USA 99 11399 11404 1:CAS:528:DC%2BD38XmslSmu7g%3D 10.1073/pnas.172398399 12177446 (Pubitemid 34920937)
3. J. Holash S. Davis N. Papadopoulos, et al. 2002 VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci USA 99 11393 11398 1:CAS:528:DC%2BD38XmslSmu7s%3D 10.1073/pnas.172398299 12177445 (Pubitemid 34920936)
4. J. Huang J.S. Frischer A. Serur, et al. 2003 Regression of established tumors and metastases by potent vascular endothelial growth factor blockade Proc Natl Acad Sci USA 100 7785 7790 1:CAS:528:DC%2BD3sXlt1WqsLo%3D 10.1073/pnas.1432908100 12805568 (Pubitemid 36760047)
5. M. Fukasawa M. Korc 2004 Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines Clin Cancer Res 10 3327 3332 1:CAS:528:DC%2BD2cXkt1Ghs7Y%3D 10.1158/1078-0432.CCR-03-0820 15161686 (Pubitemid 38685437)
6. A. Kadenhe-Chiweshe J. Papa K.W. McCrudden, et al. 2008 Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation Mol Cancer Res 6 1 9 1:CAS:528: DC%2BD1cXhtFyisLc%3D 10.1158/1541-7786.MCR-07-0101 18234958 (Pubitemid 351378161)
7. J.S. Frischer J. Huang A. Serur, et al. 2004 Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature Int J Oncol 25 549 553 1:CAS:528:DC%2BD2cXnt1OhurY%3D 15289855
8. J. Huang J.S. Frischer T. New, et al. 2004 TNP-470 promotes initial vascular sprouting in xenograft tumors Mol Cancer Ther 3 335 343 1:CAS:528:DC%2BD2cXitFCns7Y%3D 15026554 (Pubitemid 39193709)
9. A.T. Byrne L. Ross J. Holash, et al. 2003 Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model Clin Cancer Res 9 5721 5728 1:CAS:528:DC%2BD3sXpsVeju70%3D 14654557 (Pubitemid 37499496)
10. T. Inai M. Mancuso H. Hashizume, et al. 2004 Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts Am J Pathol 165 35 52 1:CAS:528:DC%2BD2cXmtFygsrc%3D 15215160 (Pubitemid 38821812)
11. F. Baffert T. Le B. Sennino, et al. 2006 Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am J Physiol Heart Circ Physiol 290 H547 559 1:CAS:528:DC%2BD28XhsFKjur0%3D 10.1152/ajpheart.00616.2005 16172161
12. X.F. Le W. Mao C. Lu, et al. 2008 Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2 Cell Cycle 7 3747 3758 1:CAS:528:DC%2BD1MXhtVKrsLc%3D 19029832
13. H. Lu R.S. Klein E.L. Schwartz 2009 Antiangiogenic and antitumor activity of 6-(2-aminoethyl) amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factortrap Clin Cancer Res 15 5136 5144 1:CAS:528:DC%2BD1MXpvFeisb8%3D 10.1158/1078-0432.CCR-08-3203 19671868
14. C. Gomez-Manzano J. Holash J. Fueyo, et al. 2008 VEGF Trap induces antiglioma effect at different stages of disease Neuro Oncol 10 940 945 10.1215/15228517-2008-061 18708344
15. S. Dalal A.M. Berry C.J. Cullinane, et al. 2005 Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family Clin Cancer Res 11 2364 2378 1:CAS:528:DC%2BD2MXisFaisrs%3D 10.1158/1078-0432. CCR-04-1201 15788688 (Pubitemid 40490198)
16. H.M. Verheul H. Hammers K. van Erp, et al. 2007 Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model Clin Cancer Res 13 4201 4208 1:CAS:528:DC%2BD2sXnvVChsLs%3D 10.1158/1078-0432.CCR-06-2553 17634549 (Pubitemid 47105984)
17. L. Hu J. Hofmann J. Holash, et al. 2005 Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model Clin Cancer Res 11 6966 6971 1:CAS:528:DC%2BD2MXhtVKiurvK 10.1158/1078-0432.CCR-05-0910 16203789 (Pubitemid 41428755)
18. P.R. Wachsberger R. Burd C. Cardi, et al. 2007 VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma Int J Radiat Oncol Biol Phys 67 1526 1537 1:CAS:528:DC%2BD2sXjs1Oisr4%3D 17234361 (Pubitemid 46467151)
19. A.C. Lockhart M.L. Rothenberg J. Dupont, et al. 2010 Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 207 214 1:CAS:528: DC%2BC3cXjtVSqt70%3D 10.1200/JCO.2009.22.9237 19949018
20. Mulay M, Limentani SA, Carroll M.; et al.(2006) Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 24:abstr 13061
21. S. Limentani R. Just A. Purdham, et al. 2008 A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results J Clin Oncol 26 abstr 3556
22. Rixe O, Verslype C, Méric JB.; et al.(2006) Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 24:abstr 13161
23. Verslype C, Spano J, Van Cutsem E.; et al.(2008) Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): Preliminary results. J Clin Oncol 26:abstr 14540
24. Rixe O, Verslype C, Khayat D.; et al.(2008) A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs). J Clin Oncol 26:abstr 3557
25. Isambert N, Freyer G, Zanetta S.; et al.(2008) A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 26:abstr 3599
26. Freyer Sr G, Fumoleau P, You B.; et al.(2008) A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 26:abstr 14539
27. Patnaik A, Pipas M, Rosen LS.; et al.(2008) A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 26:abstr 3558
28. Tew WP, Colombo N, Ray-Coquard I.; et al.(2007) VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25:abstr 5508
29. Colombo N, Mangili G, Mammoliti S.; et al.(2008) Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study. J Clin Oncol 26:abstr 14598
30. Tang P, Cohen SJ, Bjarnason GA.; et al.(2008) Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial. J Clin Oncol 26:abstr 4027.
31. Massarelli E, Miller VA, Leighl NB.; et al.(2007) Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA). J Clin Oncol 25:abstr 7627.
32. Townsley C, Hirte H, Hoskins P.; et al.(2009) A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 27:abstr 5591
33. Twardowski P, Stadler WM, Frankel P.; et al.(2009) Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial. J Clin Oncol 27:abstr e16030
34. Tarhini AA, Christensen S, Frankel P.; et al.(2009) Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol 27:abstr 9028
35. De Groot JF, Wen PY, Lamborn K.; et al.(2008) Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. J Clin Oncol 26:abstr 2020
36. W.P. Tew M. Gordon J. Murren, et al. 2010 Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors Clin Cancer Res 16 358 366 1:CAS:528:DC%2BC3cXot1Wj 10.1158/1078-0432.CCR-09-2103 20028764
37. Dupont J, Schwartz L, Koutcher J.; et al.(2004) Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. J Clin Oncol 22:abstr 3009
38. Coleman RL, Kamat A, Iyer R.; et al.(2009) Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, aflibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. J Clin Oncol 27:abstr 5549
39. Dupont J, Rothenberg ML, Spriggs DR.; et al.(2005) Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 23:abstr 3029
40. X. Zhu S. Wu W.L. Dahut C.R. Parikh 2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 186 193 1:CAS:528:DC%2BD2sXis1Kgu78%3D 10.1053/j.ajkd.2006.11.039 17261421 (Pubitemid 46178407)
41. J.R. Horowitz A. Rivard R. van der Zee, et al. 1997 Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 17 2793 2800 1:CAS:528:DyaK1cXisV2jtg%3D%3D
42. J.D. Hood C.J. Meininger M. Ziche H.J. Granger 1998 VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol 274 H1054 1058 1:CAS:528:DyaK1cXitVSjs7c%3D 9530221 (Pubitemid 28158304)
43. A.V. Chobanian G.L. Bakris H.R. Black, et al. 2003 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2560 2572 1:CAS:528:DC%2BD3sXjvFCqtrk%3D 10.1001/jama.289.19.2560 12748199 (Pubitemid 37430158)
44. J. Kanellis V. Levidiotis T. Khong, et al. 2004 A study of VEGF and its receptors in two rat models of proteinuria Nephron Physiol 96 P26 36 1:CAS:528:DC%2BD2cXptVCrtw%3D%3D 10.1159/000075577 14752241 (Pubitemid 38456626)
45. V. Eremina M. Sood J. Haigh, et al. 2003 Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J Clin Invest 111 707 716 1:CAS:528:DC%2BD3sXhvFenurs%3D 12618525 (Pubitemid 36278589)
46. B.F. Schrijvers A. Flyvbjerg A.S. De Vriese 2004 The role of vascular endothelial growth factor (VEGF) in renal pathophysiology Kidney Int 65 2003 2017 1:CAS:528:DC%2BD2cXltFKgs7c%3D 10.1111/j.1523-1755.2004.00621.x 15149314 (Pubitemid 38669987)
47. T. Kamba B.Y. Tam H. Hashizume, et al. 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart Circ Physiol 290 H560 576 1:CAS:528:DC%2BD28XhsFKjuro%3D 10.1152/ajpheart.00133. 2005 16172168
48. H. Izzedine C. Massard J.P. Spano, et al. 2010 VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management Eur J Cancer 46 439 448 1:CAS:528:DC%2BD1MXhs1Wgtb7O 10.1016/j.ejca.2009.11.001 20006922
49. S.E. Maynard J.Y. Min J. Merchan, et al. 2003 Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 649 658 1:CAS:528:DC%2BD3sXhvFentbc%3D 12618519 (Pubitemid 36278583)
50. H. Sugimoto Y. Hamano D. Charytan, et al. 2003 Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria J Biol Chem 278 12605 12608 1:CAS:528:DC%2BD3sXislGrsrg%3D 10.1074/jbc.C300012200 12538598 (Pubitemid 36800018)
51. H.P. Gerber X. Wu L. Yu, et al. 2007 Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies Proc Natl Acad Sci USA 104 3478 3483 1:CAS:528:DC%2BD2sXjtVWltbw%3D 10.1073/pnas.0611492104 17360669 (Pubitemid 46364184)
52. S. Kilickap H. Abali I. Celik 2003 Bevacizumab, bleeding, thrombosis, and warfarin J Clin Oncol 21 3542 10.1200/JCO.2003.99.046 12972536
53. I. Zachary 2001 Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor Am J Physiol Cell Physiol 280 C1375 1386 1:CAS:528:DC%2BD3MXksFKntbc%3D 11350732 (Pubitemid 32146420)
54. J.L. Spivak 2002 Polycythemia vera: myths, mechanisms, and management Blood 100 4272 4290 1:CAS:528:DC%2BD38XpsFCqsrY%3D 10.1182/blood-2001-12-0349 12393615 (Pubitemid 35429665)
55. B.Y. Tam K. Wei J.S. Rudge, et al. 2006 VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis Nat Med 12 793 800 1:CAS:528:DC%2BD28Xms1eksLs%3D 10.1038/nm1428 16799557 (Pubitemid 44050069)
56. Regeneron: Afibercept (VEGF Trap) (2010) http://www.regeneron.com/ vegftrap-cancer.html. Accessed on 01 May 2010